<DOC>
	<DOCNO>NCT00314353</DOCNO>
	<brief_summary>Bevacizumab angiogenesis inhibitor mean work stop blood vessel formation tumor . Without new blood vessel , growth tumor slow . Chemotherapy work kill cancer cell directly . This study do see colorectal cancer respond treatment combination bevacizumab chemotherapy .</brief_summary>
	<brief_title>Study Bevacizumab Combined With Capecitabine Either Oxaliplatin Irinotecan First Course Treatment Patients With Colorectal Cancer That Has Spread Beyond Colon</brief_title>
	<detailed_description>Due great patient convenience favorable toxicity profile , clinical practice see increase use combination capecitabine oxaliplatin ( CAPOX ) capecitabine irinotecan ( CAPIRI ) . Given data document improved efficacy 5-FU base chemotherapy combination bevacizumab , important investigate potential advantage add agent regimen contain capecitabine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Pathological diagnosis colon rectal cancer either colon rectum metastatic site ( beyond colon rectum ) Evidence adequate organ function ( liver , kidney , etc . ) Diagnosis anal cancer Patients candidate surgery Patients receive previous treatment Pregnant lactating woman History chronic disease ( ) serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>NSABP</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>